| |
|
|
Speakers
Have a look at some of the great people who you will have the chance to hear from at the Summit this year. Take up the opportunity to ask them all your burning questions, they won't shy away!
I am currently inviting speakers to the sessions. Watch this space to see updates and confirmed speakers.
If you would like to speak at the conference, or recommend a speaker, please email me at jstanta@eyeforpharma.com
Expand All Bios | Collapse All Bios
 |
Richard Frank MD, PhD,
Vice President, Medical Affairs and Clinical Strategy
GE Healthcare
Presentation Title:
Coming soon... |
 Speaker Bio |
| |
In the pharmaceutical industry, Dr. Frank conducted more than 100 clinical trials across all therapeutic areas and has gained regulatory approval for four drugs in the U.S. and EU, in addition to clinical pharmacology labeling for a wide range of drugs. Richard built one of the first Translational Medicine programs in the industry, including statisticians, clinicians, and technologists from gene banking to imaging. After joining GE Healthcare, Dr. Frank conducted trials for marketing approval of devices and reimbursement of diagnostic procedures. Dr. Frank has published key articles on biomarkers in drug development and is active in public-private partnerships such as the Alzheimer’s Disease Neuroimaging Initiative, serves on IoM working groups and peer-review editorial boards, chairs the FDGPETCT Technical Committee of RSNA’s Quantitative Imaging Biomarkers Alliance. and is a Fellow of the Faculty of Pharmaceutical Medicine. |
|
 |
Walter P. Carney
Head of Oncogene Science
Siemens Healthcare Diagnostics
Presentation Title:
The importance of circulating biomarkers for personalized healthcare |
Speaker Bio |
| |
Dr. Carney received his Ph.D. in Medical Microbiology and Infectious Diseases from Thomas Jefferson Medical School in Philadelphia, PA. Dr Carney is Head of the Oncogene Science organization, which functions as a center of Oncology Excellence for Siemens Dx. Previously, Dr. Carney was President of Oncogene Science and Corporate Officer for OSI Pharmaceuticals and also held the position of Vice President of Proprietary Drug Development. In addition to being the inventor of the circulating HER-2/neu protein test, Dr Carney has been a leader in integrating the FDA cleared test into the clinical management of women with HER-2 positive breast cancer. Dr Carney and the Oncogene Science Team have developed and commercialized a series of tests for guiding personalized oncology therapies. . Dr. Carney has published over 250 articles and abstracts, has been awarded over 25 patents.. Dr Carney is currently a member of the Vermillion Scientific Advisory Board. |
|
 |
Stanislaw Mikulski
Translational Medicine Leader
Hoffmann La Roche
Presentation Title:
Staying at the forefront of translational medicine |
Speaker Bio |
| |
Speaker overview coming soon... |
|
 |
Rana K. Gupta
CEO
HistoRx
Presentation Title:
Optimizing the drug development and approval process through
collaborations that reduce regulatory and market risk |
Speaker Bio |
| |
Previous to joining HistoRx, Mr. Gupta was a Managing Director at
Navigator Technology Ventures (NTV), the lead A Round investor in
HistoRx. Prior to his position with NTV, he was Product Manager for
Global Services with yet2.com, a B2B marketplace for technology
transfer. Before that, Mr. Gupta founded IndoSine U.S. Link, Ltd., a
business development company that helps clients to expand businesses in
India, China, and the U.S. While at IndoSine, Mr. Gupta co-founded a
wireless software company, International Solutions, for which he served
as Vice President of Sales and Marketing. Previous to IndoSine, he
served as Manager, PRC Investment Strategy for Zeneca Pharmaceuticals in
Beijing, China. Before joining Zeneca, he was Senior Consultant at
Arthur D. Little, Inc. and served as a member of the start-up team for
the company's Bangalore, India as well as the Cambridge office. He holds
an MBA in Finance and International Business from New York University's
Stern School of Business, an MS in Operations Research from Stanford
University, and a BA in Mathematics from Earlham College.
|
|
 |
Andy Dorner,
Senior Director of Molecular Medicine
Millennium, The Takeda Oncology Company
A preview of his talk can be found here.
Presentation Title:
The application of biomarkers in oncology clinical trials |
Speaker Bio |
| |
Andrew is currently Senior Director of the Molecular Medicine Department in Clinical Research at Millennium Pharmaceuticals, the Takeda Oncology Company and Adjunct Professor of Pharmacology in the Department of Pharmacology and Experimental Therapeutics at Boston University School of Medicine. He is presently focused on the application of Translational Medicine strategies including biomarker discovery and assay development to optimize cancer therapy and improve the benefit/risk ratio of therapeutic candidates. His previous efforts at Genetics Institute and Wyeth from 1985 to 2008 contributed to the successful approval of Recombinate, Benefix, Neumega and Infuse. Prior to joining Millennium, Andrew was Vice President, Aptamer Discovery at Archemix, Inc. Andrew received his Ph.D. from the State University of New York at Stony Brook studying poliovirus and did his postdoctoral research on avian retroviruses at Tufts University Cancer Center. |
|
 |
Stephen Little
Vice President of Personalized Healthcare
QIAGEN
Presentation Title:
Delivering personalized medicine - What is the key to commercial success? |
Speaker Bio |
| |
Dr Little has over 20 years experience in the pharmaceutical and diagnostics sectors, and as VP of Personalized Healthcare at QIAGEN will continue to help shape the personalised medicine marketplace, championing the cause for pharmaceutical partnering and companion diagnostic provision in healthcare.
Dr Stephen Little is a leading figure in the global personalized healthcare and companion diagnostics industry. Co-founder and former CEO of DxS Ltd, Dr Little led the company from its inception in 2001 to become the market leader in the provision of molecular diagnostics for cancer. In September 2009 DxS was acquired by QIAGEN, a global sample and assay company, DxS will become QIAGEN Manchester, a global Center of Excellence for Companion Diagnostics. |
|
 |
Jason Coloma
Head of Strategic Partnering
Roche Molecular Diagnostics
Presentation Title:
How to ensure long term success in delivering personalized medicine |
Speaker Bio |
| |
Head of Strategic Planning & Partnering, responsible for all strategic transactions for the Molecular Diagnostics business including research and commercial partnerships, M&A and corporate venture. Jason also leads the internal strategy projects for the business area as well as manages the strategic planning process. Jason completed his graduate studies at UC Berkeley as well as an MBA Tuck School of Business at Dartmouth. Prior to his time at Roche, Jason worked as a strategy consultant at LEK consulting working with pharmaceutical and diagnostic companies as well as private equity and venture capital firms. Finally, Jason has also held research and business positions at companies including Amgen, Cytokinetics and UCSF. |
|
 |
Dirk Haasner
Vice President of US Regulatory Policy and External Scientific Affairs
Lundbeck
Presentation Title:
Best ways to set up a seamless cross-functional team for your future products |
Speaker Bio |
| |
Dr. Dirk Haasner, Vice President, US Regulatory Policy and External Scientific Affairs at Lundbeck Inc.
In this position, Dirk is responsible for establishing and running the US Regulatory Policy group, and serves as the Lundbeck liaison for PhRMA RACC, FDA, and other external scientific relations.
Dirk joined Lundbeck USA in early 2002 as Head of Regulatory and Medical Affairs, and was responsible for the build-up and operations of US Regulatory Affairs, Medical and Scientific Affairs, Clinical Development Operations, Drug Safety, and Compliance, for all Lundbeck US development compounds before the recent merger with Ovation Pharmaceuticals, now Lundbeck Inc. in Deerfield IL.
Dirk has a PhD in Immunology and a postgraduate degree in Pharmaceutical Medicine. He started his career in Project Management at Hoffmann-La Roche, and held positions of increasing responsibility in Marketing and Global Development Project Management before being appointed Head of the Global Life-cycle Leadership Team for a top-selling Roche drug in the Pharma Business Development and Strategic Marketing department at Roche's Headquarters in Basel, Switzerland.
One of Dirk's long-term professional objectives is to strengthen communication between R&D and marketing. He is a member of the PhRMA Regulatory Affairs Coordinating Committee (RACC), a member of the International Editorial Board of the Journal of Medical Marketing, and a member of the Legal, Compliance and Regulatory Advisory Committee for BioNJ. |
|
 |
Alain Huriez
Chairman & CEO
TcLand-Expression
Presentation Title:
Companion diagnostics and the impact on the business model in the pharmaceutical and biotechnology industry |
Speaker Bio |
| |
Alain is Medical Doctor, holds a Post Graduate degree in Business Administration (MBA), a Statistics degree from the University of Paris VII, and a Masters of Pharmaco-Economics from the University of Paris I Sorbonne.
Alain Huriez MD, is since mid 2006 Chairman and Chief Executive Officer of TcLand Expression. Alain is one the company’s co-founders. From early 2003 to mid 2006 Alain was CEO at Neovacs SA, a company developing therapeutic vaccines.
Alain brings an experience of general management and financing in the biotechnology sector, in various executive positions as Associate Partner Biotech at Truffle Capital, a €220m VC fund (2002-2003), Vice-President Quintiles Europe, the world's largest CRO (1999-2002), in charge of the Biotechnology Consulting Group, a separate entity that he founded, specialized in offering strategic counsel to biotechnology listed companies in Europe and the USA. As Vice President of the Biotechnology Consulting Group, Alain set up EU subsidiaries for TSE/NASDAQ listed biotechnology companies. Alain brings also fifteen years of experience in biotech drug development, from pre-clinical to registration in several executive positions both in the pharmaceutical (GSK) and in the service industry (MDS, Innovex, Quintiles).
Prior to joining the Pharmaceutical Industry, he worked 1 year as head of an emergency room in a large teaching hospital and practiced 2 years as General Practitioner. Alain supports and triggers several biotechnology initiatives in France, is Vice President of LEEM Biotech. |
|
 |
Linda Egger
Senior Director of Scientific Liaison,
External Scientific Affairs - Oncology Licensing
Merck & Co
Presentation Title:
Today’s Merck: Successful Partnerships in Oncology and Personalized Medicine |
Speaker Bio |
| |
Linda Egger earned a BS in biology from Cook College, Rutgers University, an MS in physiology and neurobiology from Rutgers Graduate School, and a PhD in cell and developmental biology from the University of Medicine and Dentistry of New Jersey/Rutgers Graduate School. Prior to joining Merck, Linda worked at BioMetallics Inc. as a biochemist and at Wyeth-Ayerst Research as a pharmacologist. Linda joined Merck Research Laboratories in 1990. Over the next 14 years, Linda carried out basic research in the Immunology and Pharmacology departments, aimed at identifying and validating novel inflammatory targets for a variety of therapeutic areas.
Linda joined External Scientific Affairs in 2004 as a senior scientist, Scientific Licensing, where she identified and evaluated external research and licensing opportunities in the therapeutic areas of diabetes, obesity, atherosclerosis, and cardiovascular disease. In her current role as senior director, franchise licensing integrator, Linda is focusing on the identification and scientific review of oncology licensing opportunities. Linda is a member of several professional organizations including the American Association of Immunologists, the American Diabetes Association, the American Association for Cancer Research, and the Licensing Executives Society.
“Scientific licensing provides a unique opportunity to partner with other companies who share our commitment to top-notch science and passion for discovering and developing breakthrough products. Together, we can combine our strengths to deliver novel therapies that will transform human health care.”
|
|
 |
Cecilia Schott
Director of Business Development
Personalized Healthcare
Astrazeneca
Presentation Title:
Building strong and effective partnerships between pharmaceutical companies and MDx companies as the key to advancing product development |
Speaker Bio |
| |
Speaker overview coming soon... |
|
 |
Pietro Scalfaro
Director of Business Unit Diagnostics
Debiopharm
Presentation Title:
How to interface effectively molecular diagnostic during drug development to prepare for personalized medicine |
Speaker Bio |
| |
Dr Scalfaro graduated from the Faculty of Medicine, University of Lausanne, Switzerland in 1989. He received his M.D. in Gastroenterology in 1992 and practiced for over 13 years paediatric and intensive care medicine in Switzerland, Australia and France. His research interests were related to artificial ventilation, with a focus on innovative monitoring, diagnostic technologies and infectious diseases. He joined Debiopharm S.A. in 2002. After being project leader advancing and integrating the preclinical, clinical and other activities of the Alzheimer and virology programs, he held various senior management positions, and he created in particular the project and portfolio department. In 2008, he became head of Debiopharm Group's business unit for diagnostics and personalized medicine. |
|
 |
Victor Levenson
MD, President, US Biomarkers
&
Associate Professor in the Department of Radiation Oncology
Rush University Medical Center in Chicago, IL
Presentation Title:
Panel discussion: Innovative solutions for personalized medicine |
Speaker Bio |
| |
Dr. Levenson is an Associate Professor in the department of Radiation Oncology of Rush University Medical Center in Chicago, IL (www.rush.edu), and the Founder of a start-up biotechnology company US Biomarkers (www.USBiomarkers.com). He received his MD from the 2nd Moscow State Medical Institute (USSR) and his PhD in Cell and Molecular Biology from the Institute of Molecular Biology, Moscow, USSR. Dr. Levenson is the inventor of a technique (MethDet) for simultaneous evaluation of DNA methylation in multiple regions of the human genome in each sample of cell-free DNA from blood. The proof-of-principle platform of 56 genes (MethDet56) produced accurate biomarkers for differential diagnosis of inflammation, benign, and malignant diseases. Drug-specific changes of methylation patterns upon treatment and differences in baseline methylation patterns of sensitive and resistant patients bode well for the development of versatile biomarkers based on the MethDet approach. Dr. Levenson has published over 30 papers, reviews, and book chapters, has been awarded several patents, and is a member of the CDI Biosciences Board of Directors. |
|
 |
Irina Antonijevic,
MD PhD, Medical Director,
CHDI Foundation
Presentation Title:
Patient segmentation using disease modeling approaches for early clinical development and translational research |
Speaker Bio |
| |
MD from the Technical University and the Max-Planck-Institute of Psychiatry in Munich, Germany (1991). PhD in Neurophysiology from the University of Edinburgh, UK (1995). Residency at the Max-Planck-Institute of Psychiatry (1995-2001). Board Certification in Psychiatry (2000). Clinical development and biomarker research for CNS disorders at the Schering AG, Berlin (2001-2005). Habilitation and adjunct Associate Professor in Psychiatry at the Charité, Berlin University (since 2004) and guest lecturer at Columbia University, NY (since 2006). Director Translational Research at Lundbeck Research USA (2005-2009). Implemented translational biomarker research for psychiatric disorders. Since 2009, Medical Director at CHDI, focus on early clinical development and non-small molecule therapeutic interventions, as well as biomarker and new endpoint development. |
|
 |
Myla Lai-Goldman,
Chief Executive Officer, Chief Scientific Officer,
CancerguideDx
Presentation Title:
Timing is Everything: The Need for New Models for Companion Diagnostic Development
|
Speaker Bio |
| |
Myla Lai-Goldman is CancerGuide’s Chief Executive Officer, Chief Scientific Officer, and Board member.
Dr. Lai-Goldman’s primary focus is defining and executing the overall strategy for the company. Priority areas include finding and defining new products that fulfill the company’s core mission to improve the management of cancer patients.
Dr. Lai-Goldman spent more than 18 years at Laboratory Corporation of America, Holdings (LabCorp), the last 10 years as Executive Vice President, Chief Medical Officer and Chief Scientific Officer. Dr. Lai-Goldman served on LabCorp’s Executive and Management Committees, with strategic and operations responsibilities for 3 major genomic laboratories comprising more than 700 people.
During her tenure at the Company, she led all clinical, scientific and medical activities, including the introduction of more than 400 clinical assays. Her experience includes the development of partnerships, licensing, and acquisitions.
After leaving LabCorp, Dr. Lai-Goldman became a managing partner of Personalized Science, LLC, a consulting company founded to assist customers achieve successful adoption of innovative diagnostics. Dr. Lai-Goldman is Board-certified in anatomic and clinical pathology. |
|
 |
Stefan Müllner,
CEO,
Protagen AG
Presentation Title:
Discover the advantages of using autoantibodies in companion diagnostics |
Speaker Bio |
| |
Speaker overview coming soon... |
|
 |
Iain D. Miller,
Ph.D., Executive Director, Theranostics Strategy and Business Development,
Biomerieux
Presentation Title:
Promoting personalized medicine: The perspectives of a leading IVD company |
Speaker Bio |
| |
Speaker overview coming soon... |
|
 |
Damon Hostin,
Director, Business Development and Marketing,
The Center for Translational Research, Catholic Health Initiatives
Presentation Title:
Personalized medicine meets healthcare reform - A community hospital network's approach to translate innovation into improved patient care
|
Speaker Bio |
| |
Damon Hostin serves as Director of Business Development for the Center for Translational Research- a wholly owned subsidiary of Catholic Health Initiatives (CHI). CHI is a national faith-based network of 72 hospitals and 40 long-term care facilities. CHI is the sixth largest health care system in the US. At the CTR, Damon Hostin oversees the Center’s industry partnering on the discovery, development, and implementation of personalized medicine applications.
Prior to joining the CTR, Hostin was the Sr. Director for the immunodiagnostic, mAb development, and research immunotool portfolio for Strategic Diagnostics (SDIX). Earlier, as VP of Scientific Operations for GenVis Labs, a genetic analysis company purchased by Pfizer in 2008; Manager of R&D, Actinium Pharmaceuticals where he managed alliances for the development of therapeutic antibody technologies and preclinical candidates; Team Leader, Sequence Production at Celera Genomics where he was published on the Human and Drosophila genome papers in Science.
Hostin’s education includes undergraduate studies at Tulane University; Master’s studies at Harvard University; and certificate programs at The Institute for Genomic Research, the National Institutes of Health, and Wharton. |
|
 |
Matthew Rosamond
Chief of staff, Personalized Medicine practice
PricewaterhouseCoopers
Presentation Title:
The move towards personalized medicine
and what it means for the industry |
Speaker Bio |
| |
Matthew is currently the Chief of Staff for PricewaterhouseCoopers’ Personalized Medicine practice. He co-authored the firm’s recent thought leadership piece, “The New Science of Personalized Medicine,” and has spoken frequently on Personalized Medicine and Molecular Diagnostics.
Matthew holds a B.Sc. In Economics and Politics from Bristol University
Matthew Rosamond has spent ten years with PricewaterhouseCoopers’ Strategy group, working in the US, UK and Continental Europe. He has advised on over 50 transactions, working on both the buy-side and sell-side for corporate and private equity clients, and in addition has conducted a number of market entry and target search and screen strategy assignments.
Matthew has experience across a range of industries, including business services, retail, travel and leisure and industrial products. His focus over the last three years has been on the Healthcare and Life Sciences industry. Relevant experience includes:
- Commercial due diligence of a Medicare Advantage insurance provider and a Pharmacy Benefits Manager
- Business plan development for an Infusion pump manufacturer
- Molecular Diagnostic commercialization strategy for a leading Academic Medical Center
- Post merger integration for leading point of care diagnostic companies
|
|
 |
Jonathan Sheldon, Phd
Director of Translational Medicine
IDBS
Presentation Title:
Automating Biomarker Discovery and Qualification; Capturing Hypothesis, Analysis and IP |
Speaker Bio |
| |
As Director of Translational Medicine, Jonathan Sheldon is responsible for all translational research and related activities across IDBS including the recently acquired InforSense business of which he was Chief Scientific Officer.
Prior to InforSense/IDBS, Jonathan was Chief Technology Officer for Confirmant Ltd where he was responsible for developing the company's proteomics products and services. Previously he established the first bioinformatics group and was Head of Bioinformatics for 5 years at Roche Welwyn, UK participating in a number of global initiatives within the company. Dr. Sheldon holds a PhD in Molecular Biology/Biochemistry from the University of Cambridge. |
|
 |
Karen S. Long,
Vice President, Regulatory and Medical Affairs,
Abbott
Presentation Title:
Challenges in the co-development of medical products: A regulatory perspective |
Speaker Bio |
| |
Karen Long is a Divisional Vice President at Abbott with responsibility for Clinical, Regulatory and Medical Affairs for the molecular product line. Prior to joining Abbott, Karen worked at several companies, including Roche and Baxter. Notable are her twenty plus years as a regulatory professional in both the therapeutic and device industries. She has worked with many regulatory authorities worldwide to convey the importance of international standards and their acceptance. Karen has also met with international regulatory authorities to discuss new laws in their countries and to assist in the understanding of laws and regulations for devices in other countries. Karen also has a passion for personalized healthcare and works toward the communication and conveying the importance of having a combination product that is beneficial to the patient. |
|
 |
Fabio Magrini,
MD, Senior Medical Director,
MedImmune
Presentation Title:
Biomarkers and diagnostics as key elements in the decision making process in clinical development |
Speaker Bio |
| |
|
|
 |
Don Rule,
President,
Translational Software
Presentation Title:
Panel discussion: Innovative solutions for personalized medicine |
Speaker Bio |
| |
Speaker overview coming soon... |
|
|
Paul Beresford PhD,
Vice President of Business Development and Strategic Marketing
Biodesix
Presentation Title:
Coming soon... |
Speaker Bio |
| |
Dr. Beresford is Vice President of Business Development and
Strategic Marketing. His expertise includes leading groups that provide
products and services to oncology-focused pharmaceutical and
biotechnology companies for identifying and commercializing companion
diagnostics. Prior to joining Biodesix, Dr. Beresford held a number of
senior management positions at Ventana Medical Systems and Roche
Diagnostics (after the acquisition of Ventana by Roche in early 2008)
including Vice President, General Manager of Translational Diagnostics.
He received a Ph.D. in Immunology from the Sackler School of Graduate
Biomedical Sciences at Tufts University School of Medicine and was an
Instructor and Junior Investigator at the Center for Blood Research at
Harvard Medical School.
|
|
 |
Marc Hellerstein,
CSO and Founder
KineMed
Presentation Title:
Coming soon... |
Speaker Bio |
| |
Speaker overview coming soon... |
|
Back to top |
|
|
